Purchase this article with an account.
Andrea M. Keane–Myers, Dai Miyazaki, Grace Liu, Iva Dekaris, Santa Ono, M. Reza Dana; Prevention of Allergic Eye Disease by Treatment with IL-1 Receptor Antagonist. Invest. Ophthalmol. Vis. Sci. 1999;40(12):3041-3046.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. To determine the impact of interleukin-1 (IL-1) inhibition using IL-1 receptor
antagonist (IL-1Ra) in a mouse model of allergic eye disease.
methods. A/J mice sensitized and challenged with cat dander in the eye were
treated with topical IL-1Ra or vehicle alone. Control mice were treated
with IL-1Ra or vehicle but sensitized and challenged with
phosphate-buffered saline alone. Immediately after the final allergen
challenge, the mice were observed for behavioral changes and assessed
for lid injection and chemosis. The animals were then killed, eyes and
attached lids were removed for either RNA extraction or histology, and
draining lymph nodes were removed for either RNA extraction or in vitro
stimulation assays. Differences in chemokine message between
experimental and control groups were determined by RNase protection
results. Treatment with IL-1Ra in allergen-challenged animals
significantly reduced allergen-induced changes in photosensitivity
(60%, P = 0.0002), chemosis (50%, P = 0.0151), and injection (86.7%, P = 0.0068) compared with vehicle-treated controls.
Interleukin-1Ra reduced the number of degranulated mast cells and
caused a significant reduction in the number of eosinophils
infiltrating the conjunctival matrix (P < 0.001)
after allergen challenge. Examination of chemokine mRNA taken from the
conjunctiva and draining lymph nodes by RNase protection assay showed a
profound decrease in the production of a number of C–C
conclusions. These findings suggest that IL-1Ra is suppressing allergic eye disease
by a down-modulation of the recruitment of eosinophils and other
inflammatory cells essential for the immunopathogenesis of ocular
This PDF is available to Subscribers Only